<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="anec13020" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Noninvasive Electrocardiol</journal-id><journal-id journal-id-type="iso-abbrev">Ann Noninvasive Electrocardiol</journal-id><journal-id journal-id-type="pmc-domain-id">3771</journal-id><journal-id journal-id-type="pmc-domain">annnoninvas</journal-id><journal-id journal-id-type="publisher-id">ANEC</journal-id><journal-title-group><journal-title>Annals of Noninvasive Electrocardiology</journal-title></journal-title-group><issn pub-type="ppub">1082-720X</issn><issn pub-type="epub">1542-474X</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10023880</article-id><article-id pub-id-type="pmcid-ver">PMC10023880.1</article-id><article-id pub-id-type="pmcaid">10023880</article-id><article-id pub-id-type="pmcaiid">10023880</article-id><article-id pub-id-type="pmid">36527236</article-id><article-id pub-id-type="doi">10.1111/anec.13020</article-id><article-id pub-id-type="publisher-id">ANEC13020</article-id><article-id pub-id-type="other">ANEC-22-4593.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Predictors of outcome after catheter ablation for atrial fibrillation: Group analysis categorized by age and type of atrial fibrillation</article-title><alt-title alt-title-type="left-running-head">Uemura et al.</alt-title></title-group><contrib-group><contrib id="anec13020-cr-0001" contrib-type="author"><name name-style="western"><surname>Uemura</surname><given-names initials="T">Tetsuya</given-names></name><degrees>MD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0002" contrib-type="author" corresp="yes"><name name-style="western"><surname>Kondo</surname><given-names initials="H">Hidekazu</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2451-5845</contrib-id><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>hkondo@oita-u.ac.jp</email></address></contrib><contrib id="anec13020-cr-0003" contrib-type="author"><name name-style="western"><surname>Sato</surname><given-names initials="H">Hiroki</given-names></name><degrees>MD, PhD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0004" contrib-type="author"><name name-style="western"><surname>Takahashi</surname><given-names initials="M">Masaki</given-names></name><degrees>MD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0005" contrib-type="author"><name name-style="western"><surname>Shinohara</surname><given-names initials="T">Tetsuji</given-names></name><degrees>MD, PhD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0006" contrib-type="author"><name name-style="western"><surname>Mitarai</surname><given-names initials="K">Kazuki</given-names></name><degrees>MD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0007" contrib-type="author"><name name-style="western"><surname>Fukui</surname><given-names initials="A">Akira</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1670-6433</contrib-id><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0008" contrib-type="author"><name name-style="western"><surname>Hirota</surname><given-names initials="K">Kei</given-names></name><degrees>MD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0009" contrib-type="author"><name name-style="western"><surname>Fukuda</surname><given-names initials="T">Tomoko</given-names></name><degrees>MD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0010" contrib-type="author"><name name-style="western"><surname>Kodama</surname><given-names initials="N">Nozomi</given-names></name><degrees>MD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0011" contrib-type="author"><name name-style="western"><surname>Miyoshi</surname><given-names initials="M">Miho</given-names></name><degrees>MD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0012" contrib-type="author"><name name-style="western"><surname>Ogawa</surname><given-names initials="N">Naoko</given-names></name><degrees>MD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0013" contrib-type="author"><name name-style="western"><surname>Wada</surname><given-names initials="M">Masato</given-names></name><degrees>MD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0014" contrib-type="author"><name name-style="western"><surname>Yamasaki</surname><given-names initials="H">Hirochika</given-names></name><degrees>MD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0015" contrib-type="author"><name name-style="western"><surname>Iwanaga</surname><given-names initials="K">Kenzo</given-names></name><degrees>MD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0016" contrib-type="author"><name name-style="western"><surname>Uno</surname><given-names initials="A">Akihiro</given-names></name><degrees>MD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0017" contrib-type="author"><name name-style="western"><surname>Tawara</surname><given-names initials="K">Katsunori</given-names></name><degrees>MD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0018" contrib-type="author"><name name-style="western"><surname>Yonezu</surname><given-names initials="K">Keisuke</given-names></name><degrees>MD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0019" contrib-type="author"><name name-style="western"><surname>Akioka</surname><given-names initials="H">Hidefumi</given-names></name><degrees>MD, PhD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0020" contrib-type="author"><name name-style="western"><surname>Teshima</surname><given-names initials="Y">Yasushi</given-names></name><degrees>MD, PhD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0021" contrib-type="author"><name name-style="western"><surname>Yufu</surname><given-names initials="K">Kunio</given-names></name><degrees>MD, PhD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0022" contrib-type="author"><name name-style="western"><surname>Nakagawa</surname><given-names initials="M">Mikiko</given-names></name><degrees>MD, PhD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="anec13020-cr-0023" contrib-type="author"><name name-style="western"><surname>Takahashi</surname><given-names initials="N">Naohiko</given-names></name><degrees>MD, PhD</degrees><xref rid="anec13020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="anec13020-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Cardiology and Clinical Examination, Faculty of Medicine</named-content>
<institution>Oita University</institution>
<city>Yufu</city>
<named-content content-type="country-part">Oita</named-content>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Hidekazu Kondo, Department of Cardiology and Clinical Examination, Faculty of Medicine, Oita University, 1&#8208;1 Idaigaoka, Hasama, Yufu, Oita 879&#8208;5593, Japan.<break/>
Email: <email>hkondo@oita-u.ac.jp</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>12</month><year>2022</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2023</year></pub-date><volume>28</volume><issue seq="50">2</issue><issue-id pub-id-type="pmc-issue-id">431573</issue-id><issue-id pub-id-type="doi">10.1111/anec.v28.2</issue-id><elocation-id>e13020</elocation-id><history><date date-type="rev-recd"><day>07</day><month>11</month><year>2022</year></date><date date-type="received"><day>01</day><month>10</month><year>2022</year></date><date date-type="accepted"><day>08</day><month>11</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>12</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>19</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-04 23:25:13.090"><day>04</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2022 The Authors. <italic toggle="yes">Annals of Noninvasive Electrocardiology</italic> published by Wiley Periodicals LLC.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ANEC-28-e13020.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ANEC-28-e13020.pdf"/><abstract><title>Abstract</title><sec id="anec13020-sec-0001"><title>Background</title><p>The outcome of catheter ablation could probably differ among patients with atrial fibrillation (AF), depending on age and AF type. We aimed to investigate the difference in predictors of outcome after catheter ablation for AF among the patient categories divided by age and AF type.</p></sec><sec id="anec13020-sec-0002"><title>Methods and Results</title><p>A total of 396 patients with AF (mean age 65.69&#8201;&#177;&#8201;11.05&#8201;years, 111 women [28.0%]) who underwent catheter ablation from January 2018 to December 2019 were retrospectively analyzed. We divided the patients into four categories: patients with paroxysmal AF (PAF) or persistent AF (PeAF) who were 75&#8201;years or younger (&#8804;75&#8201;years) or older than 75&#8201;years (&gt;75&#8201;years). Kaplan&#8211;Meier survival analysis demonstrated that patients with PAF aged &#8804;75&#8201;years had the lowest AF recurrence among the four groups (log&#8208;rank test, <italic toggle="no">p</italic>&#160;=&#160;.0103). In the patients with PAF aged &#8804;75&#8201;years (<italic toggle="no">N</italic>&#160;=&#160;186, 46.7%), significant factors associated with recurrence were female sex (<italic toggle="no">p</italic>&#160;=&#160;.008) and diabetes (<italic toggle="no">p</italic>&#160;=&#160;.042). In the patients with PeAF aged &#8804;75&#8201;years (<italic toggle="no">N</italic>&#160;=&#160;142, 35.9%), the only significant factor associated with no recurrence was medication with a renin&#8208;angiotensin system inhibitor (<italic toggle="no">p</italic>&#160;=&#160;.044). In the patients with PAF aged &gt;75&#8201;years (<italic toggle="no">N</italic>&#160;=&#160;53, 14.4%), diabetes was significantly associated with AF recurrence (<italic toggle="no">p</italic>&#160;=&#160;.021). No significant parameters were found in the patients with PeAF aged &gt;75&#8201;years (<italic toggle="no">N</italic>&#160;=&#160;15, 4.1%).</p></sec><sec id="anec13020-sec-0003"><title>Conclusions</title><p>Our findings indicate that the risk factors for AF recurrence after catheter ablation differed by age and AF type.</p></sec></abstract><abstract abstract-type="graphical"><p>The patients with atrial fibrillation (AF) divided by age and the type AF showed significant difference of AF recurrence after catheter ablation. The significant factors associated with AF recurrence were found in each category.<boxed-text position="anchor" content-type="graphic" id="anec13020-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ANEC-28-e13020-g002.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="anec13020-kwd-0001">age</kwd><kwd id="anec13020-kwd-0002">catheter ablation</kwd><kwd id="anec13020-kwd-0003">paroxysmal atrial fibrillation</kwd><kwd id="anec13020-kwd-0004">persistent atrial fibrillation</kwd><kwd id="anec13020-kwd-0005">recurrence</kwd></kwd-group><counts><fig-count count="2"/><table-count count="4"/><page-count count="9"/><word-count count="4727"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2023</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.6 mode:remove_FC converted:18.03.2023</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="ANEC13020-cit-2001"><string-name name-style="western"><surname>Uemura</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Kondo</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Sato</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Takahashi</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Shinohara</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Mitarai</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Fukui</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Hirota</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Fukuda</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Kodama</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Miyoshi</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Ogawa</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Wada</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Yamasaki</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Iwanaga</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Uno</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Tawara</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Yonezu</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Akioka</surname>, <given-names>H.</given-names></string-name> &#8230; <string-name name-style="western"><surname>Takahashi</surname>, <given-names>N.</given-names></string-name> (<year>2023</year>). <article-title>Predictors of outcome after catheter ablation for atrial fibrillation: Group analysis categorized by age and type of atrial fibrillation</article-title>. <source>Annals of Noninvasive Electrocardiology</source>, <volume>28</volume>, <elocation-id>e13020</elocation-id>. <pub-id pub-id-type="doi">10.1111/anec.13020</pub-id><pub-id pub-id-type="pmcid">PMC10023880</pub-id><pub-id pub-id-type="pmid">36527236</pub-id></mixed-citation>
</p></notes></front><body id="anec13020-body-0001"><sec id="anec13020-sec-0004"><label>1</label><title>INTRODUCTION</title><p>Catheter ablation for atrial fibrillation (AF), especially pulmonary vein antrum isolation (PVAI), is effective for maintaining sinus rhythm; however, the efficacy is limited by the type of AF (paroxysmal or persistent) (Bhargava et al.,&#160;<xref rid="anec13020-bib-0001" ref-type="bibr">2009</xref>). The ability for catheter ablation to maintain sinus rhythm is greater in patients with paroxysmal AF (PAF) than in those with persistent AF (PeAF) (Parkash et al.,&#160;<xref rid="anec13020-bib-0002" ref-type="bibr">2010</xref>; Brooks et al.,&#160;<xref rid="anec13020-bib-0003" ref-type="bibr">2010</xref>). This could be due to progression of AF substrates out of the pulmonary vein (PV) and the presence of non&#8208;PV targets that remain after PVAI (Terricabras et al.,&#160;<xref rid="anec13020-bib-0004" ref-type="bibr">2020</xref>).</p><p>The impact of age on the outcomes after AF ablation is controversial. In studies that investigated the outcomes of AF catheter ablation focusing on differences in age, no significant variations in the overall success rate by age were noted (Natale et al.,&#160;<xref rid="anec13020-bib-0005" ref-type="bibr">2021</xref>; Bunch et al.,&#160;<xref rid="anec13020-bib-0006" ref-type="bibr">2010</xref>; Bahnson et al.,&#160;<xref rid="anec13020-bib-0007" ref-type="bibr">2022</xref>). In contrast, a small study that included patients with persistent AF undergoing cryoballoon catheter ablation showed that the older group (&gt;75&#8201;years) achieved a lower success rate (36.1%) than the younger group (&#8804;75&#8201;years) (47.0%) (Vermeersch et al.,&#160;<xref rid="anec13020-bib-0008" ref-type="bibr">2021</xref>).</p><p>There are several different predictors for AF recurrence after catheter ablation between patients with PAF and PeAF or younger and older patients (Bhargava et al.,&#160;<xref rid="anec13020-bib-0001" ref-type="bibr">2009</xref>; Buiatti et al.,&#160;<xref rid="anec13020-bib-0009" ref-type="bibr">2016</xref>; Fujino et al.,&#160;<xref rid="anec13020-bib-0010" ref-type="bibr">2020</xref>). The purpose of this study was to investigate the difference in predictors of outcome after catheter ablation for AF among patient categories divided by age and AF type.</p></sec><sec sec-type="materials-and-methods" id="anec13020-sec-0005"><label>2</label><title>MATERIALS AND METHODS</title><p>The data supporting our findings of this study are available from the corresponding author upon reasonable request.</p><sec id="anec13020-sec-0006"><label>2.1</label><title>Patient selection</title><p>The retrospective study enrolled 396 patients with PAF (<italic toggle="yes">N</italic>&#160;=&#160;239) and PeAF (<italic toggle="yes">N</italic>&#160;=&#160;157) who underwent radiofrequency catheter ablation for AF at our institute between January 2018 and December 2019. Their mean age was 65.69&#8201;&#177;&#8201;11.05&#8201;years. The study group comprised 111 females and 285 males. Sixty&#8208;eight patients were aged 76&#8201;years and older (labeled as &#8220;older&#8221;) and 328 were aged 75&#8201;years and younger (&#8220;younger&#8221;).</p><p>Patients with prior AF ablation, cardiovascular implantable electronic devices, cardiopulmonary disease, or structural heart disease were excluded from the study. PAF and PeAF were defined according to the 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement (Calkins et al.,&#160;<xref rid="anec13020-bib-0011" ref-type="bibr">2018</xref>). Briefly, PAF is defined as an episode of AF that terminates spontaneously or with intervention in &lt;7&#8201;days, and PeAF is defined as episodes that are sustained for &gt;7&#8201;days and are not self&#8208;terminating. Transthoracic and transesophageal echocardiograms were performed using the Vivid 7 ultrasound system (GE Vingmed) before ablation to evaluate the left ventricular function and left atrial diameter (LAD) and to exclude the presence of thrombi.</p><p>Experienced physicians recorded the medical history, medication regimes, and body mass index of all patients. All patients underwent physical examination, ECG, and blood testing (including renal function, Hb, HbA1c, NT&#8208;proBNP, and C&#8208;reactive protein).</p></sec><sec id="anec13020-sec-0007"><label>2.2</label><title>Follow&#8208;up</title><p>Follow&#8208;up was performed at 1, 3, 6, and 12&#8201;months after catheter ablation using a 12&#8208;lead electrocardiogram and 24&#8208;h Holter monitoring at each visit. Any atrial tachyarrhythmia lasting &#8805;1&#160;min was considered a recurrence. In addition to palpitation, patients were asked to check whether their pulse was regular in their free time. If recurrence was suspected, additional 24&#8208;h Holter monitoring was performed. The discontinuation of antiarrhythmic drugs was recommended at the 3&#8208;month follow&#8208;up.</p></sec><sec id="anec13020-sec-0008"><label>2.3</label><title>Pulmonary vein antrum isolation by catheter ablation</title><p>Contact force&#8208;guided PVAI was performed by two operators. Circumferential PVAI was performed with integrated 3D images using the open&#8208;irrigated ThermoCool SmartTouch catheter (Biosense Webster). The ablation catheter was advanced into the left atrium (LA) using a long sheath. Radiofrequency energy was delivered at 30&#8201;W in the anterior aspect of the circumferential PVAI line and at 25&#8201;W in the posterior aspect using the Stockert 70 generator system (Biosense Webster) radiofrequency generator. The operator attempted to maintain a contact force between 10 and 20&#8201;g during PVAI. While radiofrequency energy was being delivered, the catheter tip was dragged by approximately 2&#8201;mm every 5&#8211;15&#8201;s. The endpoint of PVAI was the elimination of all PV potentials recorded by a circular catheter (Lasso, Biosense Webster) placed at the ostium of the PV and the PV&#8208;to&#8208;LA block during pacing from 10 pairs of the circular catheter at 10&#160;V output with 1&#8208;ms pulse width. Isoproterenol (4&#160;&#956;g) was injected intravenously to induce AF in the non&#8208;PV foci. When a non&#8208;PV focus was identified, focal ablation was performed at the foci, except for one in the superior vena cava (SVC) where segmental isolation was performed. SVC isolation was performed if the length of the SVC sleeve was regarded &gt;30&#8201;mm (Higuchi et al.,&#160;<xref rid="anec13020-bib-0012" ref-type="bibr">2010</xref>). Cavotricuspid isthmus (CTI) linear ablation was also performed if atrial flutter was documented before ablation or induced during the ablation procedure.</p></sec><sec id="anec13020-sec-0009"><label>2.4</label><title>Statistical analysis</title><p>Baseline clinical characteristics are presented as mean with standard deviation or frequency with percentage, as appropriate. For continuous variables, normality of the distribution was tested using Shapiro&#8211;Wilk test. For continuous variables, an unpaired t&#8208;test was used to test a difference between the PAF and PeAF groups. For categorical variables, chi&#8208;square test and Fisher's exact test were used. A value of <italic toggle="yes">p</italic>&#8201;&lt;&#8201;.05 was considered significant. Potential risk factors for AF recurrence were investigated using univariate logistic regression. All computations were performed using the SPSS statistical software (version 26.0) running on Windows 10 (Microsoft).</p></sec></sec><sec sec-type="results" id="anec13020-sec-0010"><label>3</label><title>RESULTS</title><sec id="anec13020-sec-0011"><label>3.1</label><title>Patient characteristics</title><p>The characteristics of patients with AF in this study are shown in Table&#160;<xref rid="anec13020-tbl-0001" ref-type="table">1</xref>. This study enrolled a total of 396 patients (mean age 65.69&#8201;&#177;&#8201;11.05&#8201;years; 111 females). Of the 396 patients, 157 (39.6%) had PeAF, and 68 were aged &gt;75&#8201;years, with an average age of 78.9&#8201;&#177;&#8201;2.9&#8201;years. The average age of patients aged &#8804;75&#8201;years was 62.9&#8201;&#177;&#8201;10.1&#8201;years (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;.001). All patients underwent PVAI, and 208 patients (52.5%) underwent isolation of the SVC. There were no significant differences in the execution rate of SVC isolation among the four groups. Based on their age and type of AF, patients were classified into group 1: &#8804;75&#8201;years and PAF (labeled as &#8220;younger PAF,&#8221; <italic toggle="yes">n</italic>&#160;=&#160;186), group 2: &#8804;75&#8201;years and PeAF (&#8220;younger PeAF,&#8221; <italic toggle="yes">n</italic>&#160;=&#160;142), group 3: &gt;75&#8201;years and PAF (&#8220;older PAF,&#8221; <italic toggle="yes">n</italic>&#160;=&#160;53), and group 4: &gt;75&#8201;years and PeAF (&#8220;older PeAF,&#8221; <italic toggle="yes">n</italic>&#160;=&#160;15). The basic demographics of the four groups are listed in Table&#160;<xref rid="anec13020-supitem-0002" ref-type="supplementary-material">S1</xref>. There were significant differences in the number of male patients, creatinine clearance, plasma NT&#8208;proBNP level, height, body weight, the mean CHADS2 score, amiodarone medication, antiarrhythmic medication, LAD, left ventricular ejection fraction, and E/e&#8242; among the four groups. In contrast, there were no significant differences in the prevalence of hypertension, diabetes, serum creatinine levels, HbA1c, C&#8208;reactive protein, BMI, treatment with a renin&#8208;angiotensin system (RAS) inhibitor, and &#946;&#8208;blocker use among the groups.</p><table-wrap position="float" id="anec13020-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Baseline clinical characteristics of patients enrolled in this study (<italic toggle="no">n</italic>&#160;=&#160;396)</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Male sex, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">285 (72.0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age&#8212;years</td><td align="left" valign="top" rowspan="1" colspan="1">65.7&#8201;&#177;&#8201;11.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Type of AF</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Paroxysmal, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">239 (60.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Persistent, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">157 (39.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Stroke, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">34 (8.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypertension, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">238 (60.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">61 (15.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Laboratory data</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Creatinine&#8212;mg/dl</td><td align="left" valign="top" rowspan="1" colspan="1">0.91&#8201;&#177;&#8201;0.45</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Creatinine clearance&#8212;ml/min</td><td align="left" valign="top" rowspan="1" colspan="1">79.6&#8201;&#177;&#8201;31.3</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Median NT&#8208;proBNP (IQR)&#8212;pg/ml</td><td align="left" valign="top" rowspan="1" colspan="1">267 (98&#8211;604)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HbA1c&#8212;%</td><td align="left" valign="top" rowspan="1" colspan="1">5.87&#8201;&#177;&#8201;0.81</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">C&#8208;reactive protein&#8212;mg/dl</td><td align="left" valign="top" rowspan="1" colspan="1">0.19&#8201;&#177;&#8201;0.59</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Height&#8212;m</td><td align="left" valign="top" rowspan="1" colspan="1">1.64&#8201;&#177;&#8201;0.09</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Weight&#8212;kg</td><td align="left" valign="top" rowspan="1" colspan="1">67.2&#8201;&#177;&#8201;13.8</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Body mass index&#8212;kg/m<sup>2</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">24.8&#8201;&#177;&#8201;4.04</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CHADS2</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">0, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">104 (26.3)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">152 (38.4)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">98 (24.7)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">3, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">30 (7.6)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">4, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (2.8)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">5, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Medication</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ACEI/ARB, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">162 (40.9)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Beta&#8208;blocker, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">174 (43.9)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Amiodarone, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">51 (12.9)</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Antiarrhythmic, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">72 (18.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Measurements by echocardiogram</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Left atrial diameter&#8212;mm</td><td align="left" valign="top" rowspan="1" colspan="1">40.3&#8201;&#177;&#8201;0.5</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Left ventricular ejection fraction&#8212;%</td><td align="left" valign="top" rowspan="1" colspan="1">63.3&#8201;&#177;&#8201;10.2</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">E/e&#8242;</td><td align="left" valign="top" rowspan="1" colspan="1">11.4&#8201;&#177;&#8201;4.5</td></tr></tbody></table><table-wrap-foot id="anec13020-ntgp-0001"><fn id="anec13020-note-0001"><p>
<italic toggle="yes">Note</italic>: Plus&#8208;minus values are means&#8201;&#177;&#8201;SD.</p></fn><fn id="anec13020-note-0002"><p>Abbreviation: IQR, interquartile range.</p></fn></table-wrap-foot></table-wrap></sec><sec id="anec13020-sec-0012"><label>3.2</label><title>Kaplan&#8211;Meier <styled-content style="fixed-case" toggle="no">MACCE</styled-content>&#8208;free estimation</title><p>Kaplan<bold>&#8211;</bold>Meier survival analysis revealed that the AF recurrence rate was significantly different among the four groups at the 12&#8208;month follow&#8208;up (log&#8208;rank <italic toggle="yes">p</italic>&#160;=&#160;.0103, Figure&#160;<xref rid="anec13020-fig-0001" ref-type="fig">1</xref>). The AF&#8208;free survival rate of the younger PAF group was the highest, whereas that of the younger PeAF group was the lowest among the four groups.</p><fig position="float" fig-type="FIGURE" id="anec13020-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Kaplan&#8211;Meier curves showing AF recurrence free survival among four groups. There is a significant difference among four groups (log&#8208;rank <italic toggle="yes">p</italic>&#160;=&#160;.0103).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="ANEC-28-e13020-g001.jpg"/></fig></sec><sec id="anec13020-sec-0013"><label>3.3</label><title>Predictor of <styled-content style="fixed-case" toggle="no">AF</styled-content> recurrence in the younger <styled-content style="fixed-case" toggle="no">PAF</styled-content> group, aged &#8804;75&#8201;years</title><p>The baseline clinical, echocardiographic, and biochemical characteristics of patients with or without AF recurrence are shown in Table&#160;<xref rid="anec13020-tbl-0002" ref-type="table">2</xref>. The category of patients with PAF aged &#8804;75&#8201;years included 186 patients (72.6% males). Univariate analysis revealed that the significant factors associated with recurrence were female sex (<italic toggle="yes">p</italic>&#160;=&#160;.008) and diabetes (<italic toggle="yes">p</italic>&#160;=&#160;.042). In addition, multivariate analysis revealed that female sex (<italic toggle="yes">p</italic>&#160;=&#160;.005) and the prevalence of diabetes (<italic toggle="yes">p</italic>&#160;=&#160;.019) were independent predictive factors for AF recurrence.</p><table-wrap position="float" id="anec13020-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Predictor of AF recurrence in the younger PAF group</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1"/><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">AF recurrence (&#8722;)</th><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">AF recurrence (+)</th><th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">
<italic toggle="yes">p</italic> value</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Multivariate analysis</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">(<italic toggle="yes">n</italic>&#160;=&#160;169)</th><th align="left" valign="bottom" rowspan="1" colspan="1">(<italic toggle="yes">n</italic>&#160;=&#160;17)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Odds ratio</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Male sex, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">128 (75.7)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (41.2)</td><td align="left" valign="top" rowspan="1" colspan="1">.008</td><td align="left" valign="top" rowspan="1" colspan="1">0.21</td><td align="left" valign="top" rowspan="1" colspan="1">0.070&#8211;0.622</td><td align="left" valign="top" rowspan="1" colspan="1">.005</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age&#8212;years</td><td align="left" valign="top" rowspan="1" colspan="1">63.8&#8201;&#177;&#8201;10.2</td><td align="left" valign="top" rowspan="1" colspan="1">66.2&#8201;&#177;&#8201;8.4</td><td align="left" valign="top" rowspan="1" colspan="1">.335</td><td align="left" valign="top" rowspan="1" colspan="1">1.03</td><td align="left" valign="top" rowspan="1" colspan="1">0.91&#8211;1.03</td><td align="left" valign="top" rowspan="1" colspan="1">.417</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Stroke, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">15 (8.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypertension, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">99 (58.6)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (52.9)</td><td align="left" valign="top" rowspan="1" colspan="1">.797</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">18 (10.7)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (29.4)</td><td align="left" valign="top" rowspan="1" colspan="1">.042</td><td align="left" valign="top" rowspan="1" colspan="1">4.54</td><td align="left" valign="top" rowspan="1" colspan="1">1.219&#8211;16.667</td><td align="left" valign="top" rowspan="1" colspan="1">.019</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Creatinine&#8212;mg/dl</td><td align="left" valign="top" rowspan="1" colspan="1">0.9&#8201;&#177;&#8201;0.2</td><td align="left" valign="top" rowspan="1" colspan="1">0.8&#8201;&#177;&#8201;0.2</td><td align="left" valign="top" rowspan="1" colspan="1">.275</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Creatinine clearance&#8212;ml/min</td><td align="left" valign="top" rowspan="1" colspan="1">85.0&#8201;&#177;&#8201;32.8</td><td align="left" valign="top" rowspan="1" colspan="1">80.5&#8201;&#177;&#8201;27.4</td><td align="left" valign="top" rowspan="1" colspan="1">.592</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median NT&#8208;proBNP (IQR)&#8212;pg/ml</td><td align="left" valign="top" rowspan="1" colspan="1">121 (57&#8211;269)</td><td align="left" valign="top" rowspan="1" colspan="1">182 (84&#8211;543)</td><td align="left" valign="top" rowspan="1" colspan="1">.650</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HbA1c&#8212;%</td><td align="left" valign="top" rowspan="1" colspan="1">5.8&#8201;&#177;&#8201;1.0</td><td align="left" valign="top" rowspan="1" colspan="1">6.0&#8201;&#177;&#8201;0.7</td><td align="left" valign="top" rowspan="1" colspan="1">.357</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">C&#8208;reactive protein&#8212;mg/dl</td><td align="left" valign="top" rowspan="1" colspan="1">0.3&#8201;&#177;&#8201;0.4</td><td align="left" valign="top" rowspan="1" colspan="1">0.2&#8201;&#177;&#8201;0.3</td><td align="left" valign="top" rowspan="1" colspan="1">.730</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Height&#8212;m</td><td align="left" valign="top" rowspan="1" colspan="1">1.6&#8201;&#177;&#8201;0.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.6&#8201;&#177;&#8201;0.1</td><td align="left" valign="top" rowspan="1" colspan="1">.446</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weight&#8212;kg</td><td align="left" valign="top" rowspan="1" colspan="1">67.2&#8201;&#177;&#8201;13.1</td><td align="left" valign="top" rowspan="1" colspan="1">64.7&#8201;&#177;&#8201;12.1</td><td align="left" valign="top" rowspan="1" colspan="1">.456</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Body mass index&#8212;kg/m<sup>2</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">24.7&#8201;&#177;&#8201;3.9</td><td align="left" valign="top" rowspan="1" colspan="1">24.5&#8201;&#177;&#8201;3.2</td><td align="left" valign="top" rowspan="1" colspan="1">.858</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CHADS2</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">0, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">59 (34.9)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">.950</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">70 (41.4)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (47.1)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">25 (14.8)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (17.6)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">3, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (7.1)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5.9)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">4, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">5, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Medication</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ACEI/ARB, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">62 (36.7)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (41.2)</td><td align="left" valign="top" rowspan="1" colspan="1">.794</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Beta&#8208;blocker, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">72 (42.6)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (35.3)</td><td align="left" valign="top" rowspan="1" colspan="1">.616</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Amiodarone, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (8.3)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (11.8)</td><td align="left" valign="top" rowspan="1" colspan="1">.644</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Antiarrhythmic, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">42 (24.9)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (35.3)</td><td align="left" valign="top" rowspan="1" colspan="1">.386</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Echocardiographic parameter</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Left atrial diameter&#8212;mm</td><td align="left" valign="top" rowspan="1" colspan="1">38.5&#8201;&#177;&#8201;5.6</td><td align="left" valign="top" rowspan="1" colspan="1">38.2&#8201;&#177;&#8201;3.9</td><td align="left" valign="top" rowspan="1" colspan="1">.811</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Left ventricular ejection fraction&#8212;%</td><td align="left" valign="top" rowspan="1" colspan="1">65.4&#8201;&#177;&#8201;8.8</td><td align="left" valign="top" rowspan="1" colspan="1">66.8&#8201;&#177;&#8201;5.7</td><td align="left" valign="top" rowspan="1" colspan="1">.499</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">E/e&#8242;</td><td align="left" valign="top" rowspan="1" colspan="1">10.9&#8201;&#177;&#8201;4.3</td><td align="left" valign="top" rowspan="1" colspan="1">11.3&#8201;&#177;&#8201;4.9</td><td align="left" valign="top" rowspan="1" colspan="1">.706</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="anec13020-ntgp-0002"><fn id="anec13020-note-0003"><p>
<italic toggle="yes">Note</italic>: Plus&#8208;minus values are means&#8201;&#177;&#8201;SD.</p></fn><fn id="anec13020-note-0004"><p>Abbreviation: IQR, interquartile range.</p></fn></table-wrap-foot></table-wrap></sec><sec id="anec13020-sec-0014"><label>3.4</label><title>Predictor of <styled-content style="fixed-case" toggle="no">AF</styled-content> recurrence in the older <styled-content style="fixed-case" toggle="no">PAF</styled-content> group, aged &gt;75&#8201;years</title><p>The baseline clinical, echocardiographic, and biochemical characteristics of patients with or without AF recurrence are shown in Table&#160;<xref rid="anec13020-tbl-0003" ref-type="table">3</xref>. The group included 53 patients (45.3% males). Univariate analysis revealed that the only significant factor associated with recurrence was diabetes (<italic toggle="yes">p</italic>&#160;=&#160;.021), which was also confirmed as an independent predictive factor for AF recurrence in multivariate analysis (<italic toggle="yes">p</italic>&#160;=&#160;.010).</p><table-wrap position="float" id="anec13020-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Predictor of AF recurrence in the older PAF group</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1"/><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">AF recurrence (&#8722;)</th><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">AF recurrence (+)</th><th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">
<italic toggle="yes">p</italic> value</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Multivariate analysis</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">(<italic toggle="yes">n</italic>&#160;=&#160;44)</th><th align="left" valign="bottom" rowspan="1" colspan="1">(<italic toggle="yes">n</italic>&#160;=&#160;9)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Odds ratio</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Male sex, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">21 (47.7)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (33.3)</td><td align="left" valign="top" rowspan="1" colspan="1">.488</td><td align="left" valign="top" rowspan="1" colspan="1">0.75</td><td align="left" valign="top" rowspan="1" colspan="1">0.113&#8211;4.348</td><td align="left" valign="top" rowspan="1" colspan="1">.752</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age&#8212;years</td><td align="left" valign="top" rowspan="1" colspan="1">79.0&#8201;&#177;&#8201;2.7</td><td align="left" valign="top" rowspan="1" colspan="1">79.4&#8201;&#177;&#8201;3.5</td><td align="left" valign="top" rowspan="1" colspan="1">.656</td><td align="left" valign="top" rowspan="1" colspan="1">1.15</td><td align="left" valign="top" rowspan="1" colspan="1">0.833&#8211;1.587</td><td align="left" valign="top" rowspan="1" colspan="1">.377</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Stroke, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (0.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">.324</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypertension, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">31 (70.5)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (66.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (9.1)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (44.4)</td><td align="left" valign="top" rowspan="1" colspan="1">.021</td><td align="left" valign="top" rowspan="1" colspan="1">16.6</td><td align="left" valign="top" rowspan="1" colspan="1">1.219&#8211;16.667</td><td align="left" valign="top" rowspan="1" colspan="1">.010</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Creatinine&#8212;mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">0.9&#8201;&#177;&#8201;0.4</td><td align="left" valign="top" rowspan="1" colspan="1">0.9&#8201;&#177;&#8201;0.2</td><td align="left" valign="top" rowspan="1" colspan="1">.964</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Creatinine clearance&#8212;ml/min</td><td align="left" valign="top" rowspan="1" colspan="1">55.8&#8201;&#177;&#8201;16.9</td><td align="left" valign="top" rowspan="1" colspan="1">52.0&#8201;&#177;&#8201;16.6</td><td align="left" valign="top" rowspan="1" colspan="1">.541</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median NT&#8208;proBNP (IQR)&#8212;pg/ml</td><td align="left" valign="top" rowspan="1" colspan="1">251 (156&#8211;433)</td><td align="left" valign="top" rowspan="1" colspan="1">538 (345&#8211;794)</td><td align="left" valign="top" rowspan="1" colspan="1">.276</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HbA1c&#8212;%</td><td align="left" valign="top" rowspan="1" colspan="1">5.9&#8201;&#177;&#8201;0.5</td><td align="left" valign="top" rowspan="1" colspan="1">6.1&#8201;&#177;&#8201;0.5</td><td align="left" valign="top" rowspan="1" colspan="1">.266</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">C&#8208;reactive protein&#8212;mg/dl</td><td align="left" valign="top" rowspan="1" colspan="1">0.1&#8201;&#177;&#8201;0.2</td><td align="left" valign="top" rowspan="1" colspan="1">0.1&#8201;&#177;&#8201;0.1</td><td align="left" valign="top" rowspan="1" colspan="1">.205</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Height&#8212;m</td><td align="left" valign="top" rowspan="1" colspan="1">1.6&#8201;&#177;&#8201;0.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.6&#8201;&#177;&#8201;0.1</td><td align="left" valign="top" rowspan="1" colspan="1">.749</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weight&#8212;kg</td><td align="left" valign="top" rowspan="1" colspan="1">58.9&#8201;&#177;&#8201;10.3</td><td align="left" valign="top" rowspan="1" colspan="1">58.4&#8201;&#177;&#8201;13.8</td><td align="left" valign="top" rowspan="1" colspan="1">.913</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Body mass index&#8212;g/m<sup>2</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">24.0&#8201;&#177;&#8201;3.2</td><td align="left" valign="top" rowspan="1" colspan="1">24.1&#8201;&#177;&#8201;4.6</td><td align="left" valign="top" rowspan="1" colspan="1">.930</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CHADS2</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">0, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">.119</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (13.6)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (22.2)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">27 (61.4)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (22.2)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">3, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (15.9)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (44.4)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">4, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (6.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (11.1)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">5, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Medication</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ACEI/ARB, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (45.5)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (44.4)</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Beta&#8208;blocker, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (38.6)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (44.4)</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Amiodarone, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2.3)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (11.1)</td><td align="left" valign="top" rowspan="1" colspan="1">.314</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Antiarrhythmic, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (11.4)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (11.1)</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Echocardiographic parameter</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Left atrial diameter&#8212;mm</td><td align="left" valign="top" rowspan="1" colspan="1">39.6&#8201;&#177;&#8201;5.8</td><td align="left" valign="top" rowspan="1" colspan="1">39.6&#8201;&#177;&#8201;4.8</td><td align="left" valign="top" rowspan="1" colspan="1">.987</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Left ventricular ejection fraction&#8212;%</td><td align="left" valign="top" rowspan="1" colspan="1">65.6&#8201;&#177;&#8201;10.2</td><td align="left" valign="top" rowspan="1" colspan="1">65.7&#8201;&#177;&#8201;8.2</td><td align="left" valign="top" rowspan="1" colspan="1">.972</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">E/e&#8242;</td><td align="left" valign="top" rowspan="1" colspan="1">14.6&#8201;&#177;&#8201;6.1</td><td align="left" valign="top" rowspan="1" colspan="1">15.8&#8201;&#177;&#8201;5.2</td><td align="left" valign="top" rowspan="1" colspan="1">.584</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="anec13020-ntgp-0003"><fn id="anec13020-note-0005"><p>
<italic toggle="yes">Note</italic>: Plus&#8208;minus values are means&#8201;&#177;&#8201;SD.</p></fn><fn id="anec13020-note-0006"><p>Abbreviation: IQR, interquartile range.</p></fn></table-wrap-foot></table-wrap></sec><sec id="anec13020-sec-0015"><label>3.5</label><title>Predictor of <styled-content style="fixed-case" toggle="no">AF</styled-content> recurrence in the younger <styled-content style="fixed-case" toggle="no">PeAF</styled-content> group, aged &#8804;75&#8201;years</title><p>The baseline clinical, echocardiographic, and biochemical characteristics of patients with or without AF recurrence are shown in Table&#160;<xref rid="anec13020-tbl-0004" ref-type="table">4</xref>. The group included 142 patients (83.1% males). No independent factors predicting AF recurrence were identified by multivariate analysis. The only significant factor associated with no recurrence was medication with RAS inhibitors (<italic toggle="yes">p</italic>&#160;=&#160;.044).</p><table-wrap position="float" id="anec13020-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Predictor of AF recurrence in the younger PeAF group</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1"/><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">AF recurrence (&#8722;)</th><th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1">AF recurrence (+)</th><th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">
<italic toggle="yes">p</italic> value</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Multivariate analysis</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">(<italic toggle="yes">n</italic>&#160;=&#160;110)</th><th align="left" valign="bottom" rowspan="1" colspan="1">(<italic toggle="yes">n</italic>&#160;=&#160;32)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Odds ratio</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Male sex, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">91 (82.7)</td><td align="left" valign="top" rowspan="1" colspan="1">27 (84.4)</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1">1.03</td><td align="left" valign="top" rowspan="1" colspan="1">0.313&#8211;3.012</td><td align="left" valign="top" rowspan="1" colspan="1">.964</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age&#8212;years</td><td align="left" valign="top" rowspan="1" colspan="1">61.7&#8201;&#177;&#8201;10.0</td><td align="left" valign="top" rowspan="1" colspan="1">61.2&#8201;&#177;&#8201;10.1</td><td align="left" valign="top" rowspan="1" colspan="1">.812</td><td align="left" valign="top" rowspan="1" colspan="1">0.99</td><td align="left" valign="top" rowspan="1" colspan="1">0.95&#8211;1.04</td><td align="left" valign="top" rowspan="1" colspan="1">.788</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Stroke, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (5.5)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (6.3)</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypertension, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">67 (60.9)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (43.8)</td><td align="left" valign="top" rowspan="1" colspan="1">.105</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">23 (20.1)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (15.6)</td><td align="left" valign="top" rowspan="1" colspan="1">.619</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Creatinine&#8212;mg/dl</td><td align="left" valign="top" rowspan="1" colspan="1">1.0&#8201;&#177;&#8201;0.7</td><td align="left" valign="top" rowspan="1" colspan="1">1.0&#8201;&#177;&#8201;0.4</td><td align="left" valign="top" rowspan="1" colspan="1">.901</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Creatinine clearance&#8212;ml/min</td><td align="left" valign="top" rowspan="1" colspan="1">85.5&#8201;&#177;&#8201;30.5</td><td align="left" valign="top" rowspan="1" colspan="1">83.2&#8201;&#177;&#8201;27.0</td><td align="left" valign="top" rowspan="1" colspan="1">.712</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median NT&#8208;proBNP (IQR)&#8212;pg/ml</td><td align="left" valign="top" rowspan="1" colspan="1">530 (277&#8211;902)</td><td align="left" valign="top" rowspan="1" colspan="1">478 (237&#8211;663)</td><td align="left" valign="top" rowspan="1" colspan="1">.335</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HbA1c&#8212;%</td><td align="left" valign="top" rowspan="1" colspan="1">6.0&#8201;&#177;&#8201;0.6</td><td align="left" valign="top" rowspan="1" colspan="1">5.8&#8201;&#177;&#8201;0.5</td><td align="left" valign="top" rowspan="1" colspan="1">.360</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">C&#8208;reactive protein&#8212;mg/dl</td><td align="left" valign="top" rowspan="1" colspan="1">0.2&#8201;&#177;&#8201;0.5</td><td align="left" valign="top" rowspan="1" colspan="1">0.2&#8201;&#177;&#8201;0.5</td><td align="left" valign="top" rowspan="1" colspan="1">.947</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Height&#8212;m</td><td align="left" valign="top" rowspan="1" colspan="1">1.7&#8201;&#177;&#8201;0.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.7&#8201;&#177;&#8201;0.1</td><td align="left" valign="top" rowspan="1" colspan="1">0.839</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weight&#8212;kg</td><td align="left" valign="top" rowspan="1" colspan="1">71.6&#8201;&#177;&#8201;14.9</td><td align="left" valign="top" rowspan="1" colspan="1">70.7&#8201;&#177;&#8201;12.1</td><td align="left" valign="top" rowspan="1" colspan="1">.770</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Body mass index&#8212;kg/m<sup>2</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">25.6&#8201;&#177;&#8201;4.7</td><td align="left" valign="top" rowspan="1" colspan="1">25,2&#8201;&#177;&#8201;3.6</td><td align="left" valign="top" rowspan="1" colspan="1">.649</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CHADS2</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">0, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">28 (25.5)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (34.4)</td><td align="left" valign="top" rowspan="1" colspan="1">.409</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">49 (44.5)</td><td align="left" valign="top" rowspan="1" colspan="1">15 (46.9)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">28 (25.5)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (15.6)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">3, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (3.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">4, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">5, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Medication</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ACEI/ARB, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">53 (48.2)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (28.1)</td><td align="left" valign="top" rowspan="1" colspan="1">.044</td><td align="left" valign="top" rowspan="1" colspan="1">0.42</td><td align="left" valign="top" rowspan="1" colspan="1">0.164&#8211;1.010</td><td align="left" valign="top" rowspan="1" colspan="1">.059</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Beta&#8208;blocker, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">54 (49.1)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (34.4)</td><td align="left" valign="top" rowspan="1" colspan="1">.162</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Amiodarone, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">25 (22.7)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (21.9)</td><td align="left" valign="top" rowspan="1" colspan="1">1.000</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Antiarrhythmic, <italic toggle="yes">n</italic> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (10.9)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (15.6)</td><td align="left" valign="top" rowspan="1" colspan="1">.537</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Echocardiographic parameter</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Left atrial diameter&#8212;mm</td><td align="left" valign="top" rowspan="1" colspan="1">42.2&#8201;&#177;&#8201;5.1</td><td align="left" valign="top" rowspan="1" colspan="1">43.8&#8201;&#177;&#8201;4.7</td><td align="left" valign="top" rowspan="1" colspan="1">.129</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Left ventricular ejection fraction&#8212;%</td><td align="left" valign="top" rowspan="1" colspan="1">58.8&#8201;&#177;&#8201;11.2</td><td align="left" valign="top" rowspan="1" colspan="1">62.4&#8201;&#177;&#8201;8.9</td><td align="left" valign="top" rowspan="1" colspan="1">.102</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">E/e&#8242;</td><td align="left" valign="top" rowspan="1" colspan="1">10.5&#8201;&#177;&#8201;3.6</td><td align="left" valign="top" rowspan="1" colspan="1">10.6&#8201;&#177;&#8201;3.5</td><td align="left" valign="top" rowspan="1" colspan="1">.864</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot id="anec13020-ntgp-0004"><fn id="anec13020-note-0007"><p>
<italic toggle="yes">Note</italic>: Plus&#8208;minus values are means&#8201;&#177;&#8201;SD.</p></fn><fn id="anec13020-note-0008"><p>Abbreviation: IQR, interquartile range.</p></fn></table-wrap-foot></table-wrap></sec><sec id="anec13020-sec-0016"><label>3.6</label><title>Predictor of <styled-content style="fixed-case" toggle="no">AF</styled-content> recurrence in the older <styled-content style="fixed-case" toggle="no">PeAF</styled-content> group, aged &gt;75&#8201;years</title><p>The baseline clinical, echocardiographic, and biochemical characteristics of patients with or without AF recurrence are shown in Table&#160;<xref rid="anec13020-supitem-0003" ref-type="supplementary-material">S2</xref>. The group included 15 patients (53.3% males), and no significant parameters were found.</p></sec><sec id="anec13020-sec-0017"><label>3.7</label><title>Predictor of <styled-content style="fixed-case" toggle="no">AF</styled-content> recurrence in the <styled-content style="fixed-case" toggle="no">PeAF</styled-content> group regardless of age</title><p>The group of patients with persistent AF is small and with low number of events, therefore, we combined the two PeAF groups regardless of age. The basic demographics of the three groups (PAF &#8804;75, PAF &gt;75 and PeAF) are listed in Table&#160;<xref rid="anec13020-supitem-0004" ref-type="supplementary-material">S3</xref>. Kaplan<bold>&#8211;</bold>Meier survival analysis revealed that the AF recurrence rate was significantly different among the three groups at the 12&#8208;month follow&#8208;up (log&#8208;rank <italic toggle="yes">p</italic>&#160;=&#160;.0053, Figure&#160;<xref rid="anec13020-supitem-0001" ref-type="supplementary-material">S1</xref>). The PeAF group included 157 patients. The baseline clinical, echocardiographic, and biochemical characteristics of all PeAF patients with or without AF recurrence are shown in Table&#160;<xref rid="anec13020-supitem-0005" ref-type="supplementary-material">S4</xref>. Univariate analysis revealed that the factor associated with recurrence was medication with RAS inhibitors (<italic toggle="yes">p</italic>&#160;=&#160;.078), but it was not significant. No independent factors predicting AF recurrence were identified by multivariate analysis, even if we included medication with RAS inhibitors (<italic toggle="yes">p</italic>&#160;=&#160;.059).</p></sec></sec><sec sec-type="discussion" id="anec13020-sec-0018"><label>4</label><title>DISCUSSION</title><p>The main findings of this study are as follows: (1) the clinical success rates of AF ablation after 1&#160;year were significantly different among the four groups categorized by age and AF type; (2) the AF&#8208;free survival of the younger PAF group was the greatest, whereas that of the younger PeAF group was the lowest among the groups; (3) univariate analysis to predict AF recurrence in each group revealed that the prevalence of diabetes was significantly associated with AF recurrence in the younger and older PAF groups, whereas female sex was a significant predictor in the younger PAF group. In addition, medication with RAS inhibitors was significantly associated with no recurrence in the younger PeAF group; and (4) multivariate analysis revealed that the prevalence of diabetes and female sex were independent predictors of AF recurrence in the younger PAF group, whereas only the prevalence of diabetes was an independent predictor in the older PAF group.</p><p>Consistent with the results of our study, previous studies have shown that female sex and the presence of diabetes are independent predictors of AF recurrence after catheter ablation (Wang et al.,&#160;<xref rid="anec13020-bib-0013" ref-type="bibr">2020</xref>; Creta et al.,&#160;<xref rid="anec13020-bib-0014" ref-type="bibr">2019</xref>; Arora et al.,&#160;<xref rid="anec13020-bib-0015" ref-type="bibr">2018</xref>). Female sex has been reported to be associated with the presence of left atrial low&#8208;voltage areas (Huo et al.,&#160;<xref rid="anec13020-bib-0016" ref-type="bibr">2018</xref>). In addition, Takigawa et al. reported that the prevalence of non&#8208;PV triggers was significantly higher in women than in men (16% vs. 8.4%) (Takigawa et al.,&#160;<xref rid="anec13020-bib-0017" ref-type="bibr">2013</xref>). Another study reported that parasympathetic nervous activity, potentially affecting PAF vulnerability (Chen et al.,&#160;<xref rid="anec13020-bib-0018" ref-type="bibr">2014</xref>), is significantly enhanced in women than in men before and after AF ablation (Yu et al.,&#160;<xref rid="anec13020-bib-0019" ref-type="bibr">2018</xref>). The presence of these arrhythmogenic factors may contribute to higher AF recurrence rates in the younger PAF group. Sex&#8208;related differences in parasympathetic regulation diminish with age (Kuo et al.,&#160;<xref rid="anec13020-bib-0020" ref-type="bibr">1999</xref>), which could be a reason why sex differences were detected only in the younger PAF group.</p><p>Diabetes is known to promote atrial remodeling associated with AF recurrence (Wang et al.,&#160;<xref rid="anec13020-bib-0021" ref-type="bibr">2019</xref>). In our study, diabetes was associated with recurrence in patients with PAF regardless of age but not associated in patients with PeAF. As described previously, the cardiac autonomic nervous system more greatly contributes to the pathogenesis of PAF than to that of PeAF. Based on these findings, diabetes might enhance AF vulnerability by deteriorating the cardiac autonomic nervous function.</p><p>Interestingly, treatment with a RAS inhibitor was significantly associated with no recurrence of AF only in the younger PeAF group in this study. The cardioprotective effects of RAS inhibitors have been widely accepted. RAS inhibitors attenuate cardiac remodeling by suppressing atrial inflammation and fibrosis (Schieffer et al.,&#160;<xref rid="anec13020-bib-0022" ref-type="bibr">1994</xref>; Nunez et al.,&#160;<xref rid="anec13020-bib-0023" ref-type="bibr">1997</xref>; Zhu et al.,&#160;<xref rid="anec13020-bib-0024" ref-type="bibr">1997</xref>). However, the preventive effect of RAS inhibitors on AF recurrence after catheter ablation remains controversial. Previous studies have suggested that RAS inhibitors are effective for the prevention of AF recurrence after radiofrequency catheter ablation (Wang et al.,&#160;<xref rid="anec13020-bib-0025" ref-type="bibr">2016</xref>; Cui et al.,&#160;<xref rid="anec13020-bib-0026" ref-type="bibr">2015</xref>; Tian et al.,&#160;<xref rid="anec13020-bib-0027" ref-type="bibr">2019</xref>), while other studies have reported that RAS inhibitors have no preventive effect (Tayebjee et al.,&#160;<xref rid="anec13020-bib-0028" ref-type="bibr">2010</xref>; Patel et al.,&#160;<xref rid="anec13020-bib-0029" ref-type="bibr">2010</xref>). Atrial remodeling progresses depending on age. Our study may provide the potential efficacy of RAS inhibitor therapy in the younger patient category before remodeling develops with advancing age. The PeAF&#8208;limited effect of RAS inhibitors might be explained by the fact that the causes of PAF are often multifactorial (parasympathetic nervous activity, etc.) compared to those of PeAF, which are mainly considered to be atrial substrates. RAS inhibitors might not be able to affect factors such as increased parasympathetic nervous activity, resulting in no predictive value in patients with PAF. This study has some limitations. First, we followed up the patients for only 1&#160;year. This period might be too short to monitor for AF recurrence. Second, the patients were not assessed for recurrent AF using an insertable cardiac monitor. Therefore, we might have missed AF recurrence in asymptomatic patients. Third, this study was not a multicenter study and the number of patients was relatively small. Fourth, some results of this study are different from previous reports, but it seems to be related to study population. In conclusion, our findings suggest that the predictors for AF recurrence after radiofrequency catheter ablation should be considered depending on age and AF type. Appropriate management for diabetes would improve the success rate of catheter ablation for PAF irrespective of age. In addition, RAS inhibitors might play a favorable role in efficacy of catheter ablation in younger PeAF group. However, due to limitations of the study, further follow&#8208;up and a multicenter study are needed to validate the consistency and reproducibility of the results.</p></sec><sec id="anec13020-sec-1001"><label>5</label><title>AUTHOR CONTRIBUTIONS</title><p>Tetsuya Uemura and Hidekazu Kondo wrote the draft of this article and designed the study. Hiroki Sato helped to perform correct statistical analysis. Masaki Takahashi, Tetsuji Shinohara, Kazuki Mitarai, Akira Fukui, and Kei Hirota performed catheter ablation and followed&#8208;up the patients. Tomoko Fukuda, Nozomi Kodama, Miho Miyoshi, Naoko Ogawa, Masato Wada, Hirochika Yamasaki, Kenzo Iwanaga, Akihiro Uno, Katsunori Tawara, Keisuke Yonezu, Hidefumi Akioka, Yasushi Teshima, Kunio Yufu, and Mikiko Nakagawa gave the advice in terms of interpretation of the data and planning the clinical research. Naohiko Takahashi made the decision regarding final approval of this article.</p></sec><sec id="anec13020-sec-0020"><title>FUNDING INFORMATION</title><p>None.</p></sec><sec sec-type="COI-statement" id="anec13020-sec-0021"><title>CONFLICT OF INTEREST</title><p>The authors declared no conflict of interest for this article.</p></sec><sec id="anec13020-sec-0022"><title>COMPLIANCE WITH ETHICAL STANDARDS</title><p>The study was conducted in accordance with the ethics review board of Oita University. Informed consent was obtained from all subjects.</p></sec><sec id="anec13020-sec-0023"><title>CLINICAL TRIAL REGISTRATION</title><p>This study does not meet the definition of clinical trial. This study is a retrospective study and is not classified as an interventional trial.</p></sec><sec id="anec13020-sec-1002"><label>6</label><title>ETHICS STATEMENT</title><p>This retrospective study was conducted in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Institutional Review Board (IRB) of Oita University approved this study. Informed consent was obtained from all patients by the opt&#8208;out method.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="anec13020-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Figure S1
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ANEC-28-e13020-s002.pptx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="anec13020-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>
Table S1
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ANEC-28-e13020-s004.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="anec13020-supitem-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>
Table S2
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ANEC-28-e13020-s001.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="anec13020-supitem-0004" position="float" content-type="local-data" orientation="portrait"><caption><p>
Table S3
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ANEC-28-e13020-s005.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="anec13020-supitem-0005" position="float" content-type="local-data" orientation="portrait"><caption><p>
Table S4
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ANEC-28-e13020-s003.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="anec13020-sec-0019"><title>ACKNOWLEDGMENT</title><p>We thank Masae Hayashi for her excellent secretarial assistance.</p></ack><sec sec-type="data-availability" id="anec13020-sec-0025"><title>DATA AVAILABILITY STATEMENT</title><p>The data supporting our findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="anec13020-bibl-0001"><title>REFERENCES</title><ref id="anec13020-bib-0001"><mixed-citation publication-type="journal" id="anec13020-cit-0001"><string-name name-style="western"><surname>Bhargava</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Di Biase</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Mohanty</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Prasad</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname>, <given-names>D. O.</given-names></string-name>, <string-name name-style="western"><surname>Williams&#8208;Andrews</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Wazni</surname>, <given-names>O. M.</given-names></string-name>, <string-name name-style="western"><surname>Burkhardt</surname>, <given-names>J. D.</given-names></string-name>, <string-name name-style="western"><surname>Cummings</surname>, <given-names>J. E.</given-names></string-name>, <string-name name-style="western"><surname>Khaykin</surname>, <given-names>Y.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Verma</surname>, <given-names>A.</given-names></string-name> (<year>2009</year>). <article-title>Impact of atrial fibrillation and repeat catheter ablation on long&#8208;term freedom from atrial fibrillation: Results from a multicenter study</article-title>. <source>Heart Rhythm</source>, <volume>6</volume>, <fpage>1403</fpage>&#8211;<lpage>1412</lpage>.<pub-id pub-id-type="pmid">19716348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.hrthm.2009.06.014</pub-id></mixed-citation></ref><ref id="anec13020-bib-0002"><mixed-citation publication-type="journal" id="anec13020-cit-0002"><string-name name-style="western"><surname>Parkash</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Verma</surname>, <given-names>A.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Tang</surname>, <given-names>A. S.</given-names></string-name> (<year>2010</year>). <article-title>Persistent atrial fibrillation: Current approach and controversies</article-title>. <source>Current Opinion in Cardiology</source>, <volume>25</volume>, <fpage>1</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">19881338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/HCO.0b013e3283336d52</pub-id></mixed-citation></ref><ref id="anec13020-bib-0003"><mixed-citation publication-type="journal" id="anec13020-cit-0003"><string-name name-style="western"><surname>Brooks</surname>, <given-names>A. G.</given-names></string-name>, <string-name name-style="western"><surname>Stiles</surname>, <given-names>M. K.</given-names></string-name>, <string-name name-style="western"><surname>Laborderie</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Lau</surname>, <given-names>D. H.</given-names></string-name>, <string-name name-style="western"><surname>Kuklik</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Shipp</surname>, <given-names>N. J.</given-names></string-name>, <string-name name-style="western"><surname>Hsu</surname>, <given-names>L. F.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Sanders</surname>, <given-names>P.</given-names></string-name> (<year>2010</year>). <article-title>Outcomes of long&#8208;standing persistent atrial fibrillation ablation: A systematic review</article-title>. <source>Heart Rhythm</source>, <volume>7</volume>, <fpage>835</fpage>&#8211;<lpage>846</lpage>.<pub-id pub-id-type="pmid">20206320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.hrthm.2010.01.017</pub-id></mixed-citation></ref><ref id="anec13020-bib-0004"><mixed-citation publication-type="journal" id="anec13020-cit-0004"><string-name name-style="western"><surname>Terricabras</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Piccini</surname>, <given-names>J. P.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Verma</surname>, <given-names>A.</given-names></string-name> (<year>2020</year>). <article-title>Ablation of persistent atrial fibrillation: Challenges and solutions</article-title>. <source>Journal of Cardiovascular Electrophysiology</source>, <volume>31</volume>, <fpage>1809</fpage>&#8211;<lpage>1821</lpage>.<pub-id pub-id-type="pmid">31828883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jce.14311</pub-id></mixed-citation></ref><ref id="anec13020-bib-0005"><mixed-citation publication-type="journal" id="anec13020-cit-0005"><string-name name-style="western"><surname>Natale</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>Mohanty</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Trivedi</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Baqai</surname>, <given-names>F. M.</given-names></string-name>, <string-name name-style="western"><surname>Gallinghouse</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Della Rocca</surname>, <given-names>D. G.</given-names></string-name>, <string-name name-style="western"><surname>Gianni</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>MacDonald</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Mayedo</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Burkhardt</surname>, <given-names>J. D.</given-names></string-name>, <string-name name-style="western"><surname>Gallinghouse</surname>, <given-names>G. J.</given-names></string-name>, <string-name name-style="western"><surname>al&#8208;Ahmad</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Horton</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Bassiouny</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>di Biase</surname>, <given-names>L.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Natale</surname>, <given-names>A.</given-names></string-name> (<year>2021</year>). <article-title>Arrhythmia profile and ablation&#8208;outcome in elderly women with atrial fibrillation undergoing first catheter ablation</article-title>. <source>Pacing and Clinical Electrophysiology</source>, <volume>44</volume>, <fpage>835</fpage>&#8211;<lpage>842</lpage>.<pub-id pub-id-type="pmid">33742711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pace.14223</pub-id></mixed-citation></ref><ref id="anec13020-bib-0006"><mixed-citation publication-type="journal" id="anec13020-cit-0006"><string-name name-style="western"><surname>Bunch</surname>, <given-names>T. J.</given-names></string-name>, <string-name name-style="western"><surname>Weiss</surname>, <given-names>J. P.</given-names></string-name>, <string-name name-style="western"><surname>Crandall</surname>, <given-names>B. G.</given-names></string-name>, <string-name name-style="western"><surname>May</surname>, <given-names>H. T.</given-names></string-name>, <string-name name-style="western"><surname>Bair</surname>, <given-names>T. L.</given-names></string-name>, <string-name name-style="western"><surname>Osborn</surname>, <given-names>J. S.</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname>, <given-names>J. L.</given-names></string-name>, <string-name name-style="western"><surname>Lappe</surname>, <given-names>D. L.</given-names></string-name>, <string-name name-style="western"><surname>Muhlestein</surname>, <given-names>J. B.</given-names></string-name>, <string-name name-style="western"><surname>Nelson</surname>, <given-names>J.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Day</surname>, <given-names>J. D.</given-names></string-name> (<year>2010</year>). <article-title>Long&#8208;term clinical efficacy and risk of catheter ablation for atrial fibrillation in octogenarians</article-title>. <source>Pacing and Clinical Electrophysiology</source>, <volume>33</volume>, <fpage>146</fpage>&#8211;<lpage>152</lpage>.<pub-id pub-id-type="pmid">19889181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1540-8159.2009.02604.x</pub-id></mixed-citation></ref><ref id="anec13020-bib-0007"><mixed-citation publication-type="journal" id="anec13020-cit-0007"><string-name name-style="western"><surname>Bahnson</surname>, <given-names>T. D.</given-names></string-name>, <string-name name-style="western"><surname>Giczewska</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Mark</surname>, <given-names>D. B.</given-names></string-name>, <string-name name-style="western"><surname>Russo</surname>, <given-names>A. M.</given-names></string-name>, <string-name name-style="western"><surname>Monahan</surname>, <given-names>K. H.</given-names></string-name>, <string-name name-style="western"><surname>al&#8208;Khalidi</surname>, <given-names>H. R.</given-names></string-name>, <string-name name-style="western"><surname>Silverstein</surname>, <given-names>A. P.</given-names></string-name>, <string-name name-style="western"><surname>Poole</surname>, <given-names>J. E.</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname>, <given-names>K. L.</given-names></string-name>, <string-name name-style="western"><surname>Packer</surname>, <given-names>D. L.</given-names></string-name>, &amp; <collab collab-type="authors">for the CABANA Investigators</collab>
. (<year>2022</year>). <article-title>Association between age and outcomes of catheter ablation versus medical therapy for atrial fibrillation: Results from the CABANA trial</article-title>. <source>Circulation</source>, <volume>145</volume>, <fpage>796</fpage>&#8211;<lpage>804</lpage>.<pub-id pub-id-type="pmid">34933570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.121.055297</pub-id><pub-id pub-id-type="pmcid">PMC9003625</pub-id></mixed-citation></ref><ref id="anec13020-bib-0008"><mixed-citation publication-type="journal" id="anec13020-cit-0008"><string-name name-style="western"><surname>Vermeersch</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Abugattas</surname>, <given-names>J. P.</given-names></string-name>, <string-name name-style="western"><surname>Varnavas</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>de Cocker</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Schwagten</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Sieira</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Asmundis</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Chierchia</surname>, <given-names>G. B.</given-names></string-name>, &amp; <string-name name-style="western"><surname>de Greef</surname>, <given-names>Y.</given-names></string-name> (<year>2021</year>). <article-title>Efficacy and safety of the second&#8208;generation cryoballoon ablation for the treatment of persistent atrial fibrillation in elderly patients</article-title>. <source>Journal of Arrhythmia</source>, <volume>37</volume>, <fpage>626</fpage>&#8211;<lpage>634</lpage>.<pub-id pub-id-type="pmid">34141015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/joa3.12531</pub-id><pub-id pub-id-type="pmcid">PMC8207396</pub-id></mixed-citation></ref><ref id="anec13020-bib-0009"><mixed-citation publication-type="journal" id="anec13020-cit-0009"><string-name name-style="western"><surname>Buiatti</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Kaess</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Reents</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Semmler</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>Telishveska</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Bourier</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Kornmayer</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Kottmaier</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Hessling</surname>, <given-names>G.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Deisenhofer</surname>, <given-names>I.</given-names></string-name> (<year>2016</year>). <article-title>Catheter ablation for &#8220;lone&#8221; atrial fibrillation: Efficacy and predictors of recurrence</article-title>. <source>Journal of Cardiovascular Electrophysiology</source>, <volume>27</volume>, <fpage>536</fpage>&#8211;<lpage>541</lpage>.<pub-id pub-id-type="pmid">26799683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jce.12936</pub-id></mixed-citation></ref><ref id="anec13020-bib-0010"><mixed-citation publication-type="journal" id="anec13020-cit-0010"><string-name name-style="western"><surname>Fujino</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Yuzawa</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Kinoshita</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Koike</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Shinohara</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Akitsu</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Yano</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Suzuki</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Yamada</surname>, <given-names>M.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Ikeda</surname>, <given-names>T.</given-names></string-name> (<year>2020</year>). <article-title>Clinical factors associated with a successful catheter ablation outcome in elderly patients with atrial fibrillation</article-title>. <source>International Heart Journal</source>, <volume>61</volume>, <fpage>21</fpage>&#8211;<lpage>28</lpage>.<pub-id pub-id-type="pmid">31956136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1536/ihj.19-226</pub-id></mixed-citation></ref><ref id="anec13020-bib-0011"><mixed-citation publication-type="journal" id="anec13020-cit-0011"><string-name name-style="western"><surname>Calkins</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Hindricks</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Cappato</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname>, <given-names>Y. H.</given-names></string-name>, <string-name name-style="western"><surname>Saad</surname>, <given-names>E. B.</given-names></string-name>, <string-name name-style="western"><surname>Aguinaga</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Akar</surname>, <given-names>J. G.</given-names></string-name>, <string-name name-style="western"><surname>Badhwar</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>Brugada</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Camm</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname>, <given-names>P. S.</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname>, <given-names>S. A.</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname>, <given-names>M. K.</given-names></string-name>, <string-name name-style="western"><surname>Cosedis Nielsen</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Curtis</surname>, <given-names>A. B.</given-names></string-name>, <string-name name-style="western"><surname>Davies</surname>, <given-names>D. W.</given-names></string-name>, <string-name name-style="western"><surname>Day</surname>, <given-names>J. D.</given-names></string-name>, <string-name name-style="western"><surname>d'Avila</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>(Natasja) de Groot</surname>, <given-names>N. M. S.</given-names></string-name>, &#8230; <string-name name-style="western"><surname>Willems</surname>, <given-names>S.</given-names></string-name> (<year>2018</year>). <article-title>2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation</article-title>. <source>Europace</source>, <volume>20</volume>, <fpage>e1</fpage>&#8211;<lpage>e160</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/europace/eux274</pub-id><pub-id pub-id-type="pmcid">PMC5834122</pub-id><pub-id pub-id-type="pmid">29016840</pub-id></mixed-citation></ref><ref id="anec13020-bib-0012"><mixed-citation publication-type="journal" id="anec13020-cit-0012"><string-name name-style="western"><surname>Higuchi</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Yamauchi</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Hirao</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Sasaki</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Hachiya</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Sekiguchi</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Nitta</surname>, <given-names>J.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Isobe</surname>, <given-names>M.</given-names></string-name> (<year>2010</year>). <article-title>Superior vena cava as initiator of atrial fibrillation: Factors related to its arrhythmogenicity</article-title>. <source>Heart Rhythm</source>, <volume>7</volume>, <fpage>1186</fpage>&#8211;<lpage>1191</lpage>.<pub-id pub-id-type="pmid">20470902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.hrthm.2010.05.017</pub-id></mixed-citation></ref><ref id="anec13020-bib-0013"><mixed-citation publication-type="journal" id="anec13020-cit-0013"><string-name name-style="western"><surname>Wang</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Truong</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Black&#8208;Maier</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Green</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname>, <given-names>K. B.</given-names></string-name>, <string-name name-style="western"><surname>Barnett</surname>, <given-names>A. S.</given-names></string-name>, <string-name name-style="western"><surname>Febre</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Loring</surname>, <given-names>Z.</given-names></string-name>, <string-name name-style="western"><surname>al&#8208;Khatib</surname>, <given-names>S. M.</given-names></string-name>, <string-name name-style="western"><surname>Atwater</surname>, <given-names>B. D.</given-names></string-name>, <string-name name-style="western"><surname>Daubert</surname>, <given-names>J. P.</given-names></string-name>, <string-name name-style="western"><surname>Frazier&#8208;Mills</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Hegland</surname>, <given-names>D. D.</given-names></string-name>, <string-name name-style="western"><surname>Jackson</surname>, <given-names>K. P.</given-names></string-name>, <string-name name-style="western"><surname>Jackson</surname>, <given-names>L. R.</given-names></string-name>, <string-name name-style="western"><surname>Koontz</surname>, <given-names>J. I.</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname>, <given-names>R. K.</given-names></string-name>, <string-name name-style="western"><surname>Pokorney</surname>, <given-names>S. D.</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname>, <given-names>A. Y.</given-names></string-name>, &#8230; <string-name name-style="western"><surname>Piccini</surname>, <given-names>J. P.</given-names></string-name> (<year>2020</year>). <article-title>Catheter ablation of atrial fibrillation in patients with diabetes mellitus</article-title>. <source>Heart Rhythm</source>, <volume>1</volume>(<issue>3</issue>), <fpage>180</fpage>&#8211;<lpage>188</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.hroo.2020.04.006</pub-id><pub-id pub-id-type="pmcid">PMC8183889</pub-id><pub-id pub-id-type="pmid">34113872</pub-id></mixed-citation></ref><ref id="anec13020-bib-0014"><mixed-citation publication-type="journal" id="anec13020-cit-0014"><string-name name-style="western"><surname>Creta</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Providencia</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Adragao</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>de Asmundis</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Chun</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Chierchia</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Defaye</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Schmidt</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Anselme</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Finlay</surname>, <given-names>M.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Hunter</surname>, <given-names>R. J.</given-names></string-name> (<year>2019</year>). <article-title>Impact of type&#8208;2 diabetes mellitus on the outcomes of catheter ablation of atrial fibrillation (European observational multicentre study)</article-title>. <source>The American Journal of Cardiology</source>, <volume>125</volume>, <fpage>901</fpage>&#8211;<lpage>906</lpage>.<pub-id pub-id-type="pmid">31973808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjcard.2019.12.037</pub-id></mixed-citation></ref><ref id="anec13020-bib-0015"><mixed-citation publication-type="journal" id="anec13020-cit-0015"><string-name name-style="western"><surname>Arora</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Lahewala</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Tripathi</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Mehta</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname>, <given-names>V.</given-names></string-name>, <string-name name-style="western"><surname>Chandramohan</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Lemor</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Dave</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname>, <given-names>N. V.</given-names></string-name>, <string-name name-style="western"><surname>Palamaner Subash Shantha</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western"><surname>Viles&#8208;Gonzalez</surname>, <given-names>J.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Deshmukh</surname>, <given-names>A.</given-names></string-name> (<year>2018</year>). <article-title>Causes and predictors of readmission in patients with atrial fibrillation undergoing catheter ablation: A national population national study</article-title>. <source>Journal of the American Heart Association</source>, <volume>7</volume>, <elocation-id>e009294</elocation-id>.<pub-id pub-id-type="pmid">29907655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/JAHA.118.009294</pub-id><pub-id pub-id-type="pmcid">PMC6220533</pub-id></mixed-citation></ref><ref id="anec13020-bib-0016"><mixed-citation publication-type="journal" id="anec13020-cit-0016"><string-name name-style="western"><surname>Huo</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Gaspar</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Pohl</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Sitzy</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Richter</surname>, <given-names>U.</given-names></string-name>, <string-name name-style="western"><surname>Neudeck</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Mayer</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Kronborg</surname>, <given-names>M. B.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Piorkowski</surname>, <given-names>C.</given-names></string-name> (<year>2018</year>). <article-title>Prevalence and predictors of low voltage zones in the left atrium in patients with atrial fibrillation</article-title>. <source>Europace</source>, <volume>20</volume>, <fpage>956</fpage>&#8211;<lpage>962</lpage>.<pub-id pub-id-type="pmid">28605524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/europace/eux082</pub-id></mixed-citation></ref><ref id="anec13020-bib-0017"><mixed-citation publication-type="journal" id="anec13020-cit-0017"><string-name name-style="western"><surname>Takigawa</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Kuwahara</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Takahashi</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Watari</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Okubo</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Takahashi</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Takagi</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Kuroda</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Osaka</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Kawaguchi</surname>, <given-names>N.</given-names></string-name>, <string-name name-style="western"><surname>Yamao</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Nakashima</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Sugiyama</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Akiyama</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Kamiishi</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Kimura</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Hikita</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Hirao</surname>, <given-names>K.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Isobe</surname>, <given-names>M.</given-names></string-name> (<year>2013</year>). <article-title>Differences in catheter ablation of paroxysmal atrial fibrillation between males and females</article-title>. <source>International Journal of Cardiology</source>, <volume>168</volume>, <fpage>1984</fpage>&#8211;<lpage>1991</lpage>.<pub-id pub-id-type="pmid">23782910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijcard.2012.12.101</pub-id></mixed-citation></ref><ref id="anec13020-bib-0018"><mixed-citation publication-type="journal" id="anec13020-cit-0018"><string-name name-style="western"><surname>Chen</surname>, <given-names>P. S.</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname>, <given-names>L. S.</given-names></string-name>, <string-name name-style="western"><surname>Fishbein</surname>, <given-names>M. C.</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname>, <given-names>S. F.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Nattel</surname>, <given-names>S.</given-names></string-name> (<year>2014</year>). <article-title>Role of the autonomic nervous system in atrial fibrillation: Pathophysiology and therapy</article-title>. <source>Circulation Research</source>, <volume>114</volume>, <fpage>1500</fpage>&#8211;<lpage>1515</lpage>.<pub-id pub-id-type="pmid">24763467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.114.303772</pub-id><pub-id pub-id-type="pmcid">PMC4043633</pub-id></mixed-citation></ref><ref id="anec13020-bib-0019"><mixed-citation publication-type="journal" id="anec13020-cit-0019"><string-name name-style="western"><surname>Yu</surname>, <given-names>H. T.</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname>, <given-names>P. S.</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname>, <given-names>T. H.</given-names></string-name>, <string-name name-style="western"><surname>Uhm</surname>, <given-names>J. S.</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname>, <given-names>J. Y.</given-names></string-name>, <string-name name-style="western"><surname>Joung</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname>, <given-names>M. H.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Pak</surname>, <given-names>H. N.</given-names></string-name> (<year>2018</year>). <article-title>Poor rhythm outcome of catheter ablation for early&#8208;onset atrial fibrillation in woman: Mechanistic insight</article-title>. <source>Circulation Journal</source>, <volume>82</volume>, <fpage>2259</fpage>&#8211;<lpage>2268</lpage>.<pub-id pub-id-type="pmid">29887578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1253/circj.CJ-17-1358</pub-id></mixed-citation></ref><ref id="anec13020-bib-0020"><mixed-citation publication-type="journal" id="anec13020-cit-0020"><string-name name-style="western"><surname>Kuo</surname>, <given-names>T. B.</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname>, <given-names>C. C.</given-names></string-name>, <string-name name-style="western"><surname>Li</surname>, <given-names>C. L.</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname>, <given-names>C. F.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Chou</surname>, <given-names>P.</given-names></string-name> (<year>1999</year>). <article-title>Effect of aging on gender differences in neural control of heart rate</article-title>. <source>The American Journal of Physiology</source>, <volume>277</volume>, <fpage>H2233</fpage>&#8211;<lpage>H2239</lpage>.<pub-id pub-id-type="pmid">10600841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpheart.1999.277.6.H2233</pub-id></mixed-citation></ref><ref id="anec13020-bib-0021"><mixed-citation publication-type="journal" id="anec13020-cit-0021"><string-name name-style="western"><surname>Wang</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Green</surname>, <given-names>J. B.</given-names></string-name>, <string-name name-style="western"><surname>Halperin</surname>, <given-names>J. L.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Piccini</surname>, <given-names>J. P.</given-names></string-name> (<year>2019</year>). <article-title>Atrial fibrillation and diabetes mellitus</article-title>. <source>Journal of the American College of Cardiology</source>, <volume>74</volume>, <fpage>1107</fpage>&#8211;<lpage>1115</lpage>.<pub-id pub-id-type="pmid">31439220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2019.07.020</pub-id></mixed-citation></ref><ref id="anec13020-bib-0022"><mixed-citation publication-type="journal" id="anec13020-cit-0022"><string-name name-style="western"><surname>Schieffer</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>Wirger</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Meybrunn</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western"><surname>Seitz</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Holtz</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Riede</surname>, <given-names>U. N.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Drexler</surname>, <given-names>H.</given-names></string-name> (<year>1994</year>). <article-title>Comparative effects of chronic angiotensin&#8208;converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat</article-title>. <source>Circulation</source>, <volume>89</volume>, <fpage>2273</fpage>&#8211;<lpage>2282</lpage>.<pub-id pub-id-type="pmid">8181153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.cir.89.5.2273</pub-id></mixed-citation></ref><ref id="anec13020-bib-0023"><mixed-citation publication-type="journal" id="anec13020-cit-0023"><string-name name-style="western"><surname>Nunez</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Hosoya</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Susic</surname>, <given-names>D.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Frohlich</surname>, <given-names>E. D.</given-names></string-name> (<year>1997</year>). <article-title>Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR</article-title>. <source>Hypertension</source>, <volume>29</volume>, <fpage>519</fpage>&#8211;<lpage>524</lpage>.<pub-id pub-id-type="pmid">9039153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.hyp.29.1.519</pub-id></mixed-citation></ref><ref id="anec13020-bib-0024"><mixed-citation publication-type="journal" id="anec13020-cit-0024"><string-name name-style="western"><surname>Zhu</surname>, <given-names>Y. C.</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname>, <given-names>Y. Z.</given-names></string-name>, <string-name name-style="western"><surname>Gohlke</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Stauss</surname>, <given-names>H. M.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Unger</surname>, <given-names>T.</given-names></string-name> (<year>1997</year>). <article-title>Effects of angiotensin&#8208;converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy</article-title>. <source>The American Journal of Cardiology</source>, <volume>80</volume>, <fpage>110A</fpage>&#8211;<lpage>117A</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0002-9149(97)00465-7</pub-id><pub-id pub-id-type="pmid">9293963</pub-id></mixed-citation></ref><ref id="anec13020-bib-0025"><mixed-citation publication-type="journal" id="anec13020-cit-0025"><string-name name-style="western"><surname>Wang</surname>, <given-names>Q.</given-names></string-name>, <string-name name-style="western"><surname>Shang</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>, <given-names>Z.</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Qiu</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Li</surname>, <given-names>H.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Zheng</surname>, <given-names>L.</given-names></string-name> (<year>2016</year>). <article-title>Perindopril for the prevention of atrial fibrillation recurrence after radiofrequency catheter ablation: One&#8208;year experience</article-title>. <source>Heart Rhythm</source>, <volume>13</volume>, <fpage>2040</fpage>&#8211;<lpage>2047</lpage>.<pub-id pub-id-type="pmid">27374309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.hrthm.2016.06.039</pub-id></mixed-citation></ref><ref id="anec13020-bib-0026"><mixed-citation publication-type="journal" id="anec13020-cit-0026"><string-name name-style="western"><surname>Cui</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname>, <given-names>C.</given-names></string-name>, <string-name name-style="western"><surname>Long</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname>, <given-names>X.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Zhang</surname>, <given-names>G.</given-names></string-name> (<year>2015</year>). <article-title>Effect of valsartan on atrial fibrillation recurrence following pulmonary vein isolation in patients</article-title>. <source>Experimental and Therapeutic Medicine</source>, <volume>9</volume>, <fpage>631</fpage>&#8211;<lpage>635</lpage>.<pub-id pub-id-type="pmid">25574246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2014.2143</pub-id><pub-id pub-id-type="pmcid">PMC4280931</pub-id></mixed-citation></ref><ref id="anec13020-bib-0027"><mixed-citation publication-type="journal" id="anec13020-cit-0027"><string-name name-style="western"><surname>Tian</surname>, <given-names>F.</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname>, <given-names>P.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Zang</surname>, <given-names>Y.</given-names></string-name> (<year>2019</year>). <article-title>Effects of candesartan on relapse of atrial fibrillation after radio&#8208;frequency ablation and duration of atrial fibrillation attack</article-title>. <source>International Journal of Clinical and Experimental Medicine</source>, <volume>12</volume>, <fpage>1011</fpage>&#8211;<lpage>1017</lpage>.</mixed-citation></ref><ref id="anec13020-bib-0028"><mixed-citation publication-type="journal" id="anec13020-cit-0028"><string-name name-style="western"><surname>Tayebjee</surname>, <given-names>M. H.</given-names></string-name>, <string-name name-style="western"><surname>Creta</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Moder</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Hunter</surname>, <given-names>R. J.</given-names></string-name>, <string-name name-style="western"><surname>Earley</surname>, <given-names>M. J.</given-names></string-name>, <string-name name-style="western"><surname>Dhinoja</surname>, <given-names>M. B.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Schilling</surname>, <given-names>R. J.</given-names></string-name> (<year>2010</year>). <article-title>Impact of angiotensin&#8208;converting enzyme&#8208;inhibitors and angiotensin receptor blockers on long&#8208;term outcome of catheter ablation for atrial fibrillation</article-title>. <source>Europace</source>, <volume>12</volume>, <fpage>1537</fpage>&#8211;<lpage>1542</lpage>.<pub-id pub-id-type="pmid">20682557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/europace/euq284</pub-id></mixed-citation></ref><ref id="anec13020-bib-0029"><mixed-citation publication-type="journal" id="anec13020-cit-0029"><string-name name-style="western"><surname>Patel</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western"><surname>Mohanty</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>Di Biase</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname>, <given-names>Y.</given-names></string-name>, <string-name name-style="western"><surname>Shaheen</surname>, <given-names>M. H.</given-names></string-name>, <string-name name-style="western"><surname>Sanchez</surname>, <given-names>J. E.</given-names></string-name>, <string-name name-style="western"><surname>Horton</surname>, <given-names>R. P.</given-names></string-name>, <string-name name-style="western"><surname>Gallinghouse</surname>, <given-names>G. J.</given-names></string-name>, <string-name name-style="western"><surname>Zagrodzky</surname>, <given-names>J. D.</given-names></string-name>, <string-name name-style="western"><surname>Bailey</surname>, <given-names>S. M.</given-names></string-name>, &amp; <string-name name-style="western"><surname>Burkhardt</surname>, <given-names>J. D.</given-names></string-name> (<year>2010</year>). <article-title>The impact of statins and renin&#8208;angiotensin&#8208;aldosterone system blockers on pulmonary vein antrum isolation outcomes in post&#8208;menopausal females</article-title>. <source>Europace</source>, <volume>12</volume>, <fpage>322</fpage>&#8211;<lpage>330</lpage>.<pub-id pub-id-type="pmid">20064822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/europace/eup387</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>